ZBIO Valuation

Zenas Biopharma Inc

Add to Watchlist

Advanced Chart

32.460

+1.93(6.322%)1D

ZBIO Relative Valuation

ZBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ZBIO is overvalued; if below, it's undervalued.

Historical Valuation

Zenas Biopharma Inc (ZBIO) is now in the Fair zone, suggesting that its current forward PS ratio of 30.53 is considered Fairly compared with the five-year average of -3.21. The fair price of Zenas Biopharma Inc (ZBIO) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：32.16

Fair

-6.92

Trailing

Forward

-6.05

EV/EBITDA

Zenas Biopharma Inc. (ZBIO) has a current EV/EBITDA of -6.05. The 5-year average EV/EBITDA is -1.16. The thresholds are as follows: Strongly Undervalued below -5.08, Undervalued between -5.08 and -3.12, Fairly Valued between 0.79 and -3.12, Overvalued between 0.79 and 2.75, and Strongly Overvalued above 2.75. The current Forward EV/EBITDA of -6.05 falls within the Strongly Undervalued range.

-7.07

EV/EBIT

Zenas Biopharma Inc. (ZBIO) has a current EV/EBIT of -7.07. The 5-year average EV/EBIT is -1.23. The thresholds are as follows: Strongly Undervalued below -5.14, Undervalued between -5.14 and -3.19, Fairly Valued between 0.72 and -3.19, Overvalued between 0.72 and 2.68, and Strongly Overvalued above 2.68. The current Forward EV/EBIT of -7.07 falls within the Strongly Undervalued range.

30.53

Zenas Biopharma Inc. (ZBIO) has a current PS of 30.53. The 5-year average PS is 35.13. The thresholds are as follows: Strongly Undervalued below -54.97, Undervalued between -54.97 and -9.92, Fairly Valued between 80.18 and -9.92, Overvalued between 80.18 and 125.23, and Strongly Overvalued above 125.23. The current Forward PS of 30.53 falls within the Historic Trend Line -Fairly Valued range.

-7.85

P/OCF

Zenas Biopharma Inc. (ZBIO) has a current P/OCF of -7.85. The 5-year average P/OCF is -2.76. The thresholds are as follows: Strongly Undervalued below -5.61, Undervalued between -5.61 and -4.19, Fairly Valued between -1.34 and -4.19, Overvalued between -1.34 and 0.08, and Strongly Overvalued above 0.08. The current Forward P/OCF of -7.85 falls within the Strongly Undervalued range.

-8.89

P/FCF

Zenas Biopharma Inc. (ZBIO) has a current P/FCF of -8.89. The 5-year average P/FCF is -2.77. The thresholds are as follows: Strongly Undervalued below -5.73, Undervalued between -5.73 and -4.25, Fairly Valued between -1.29 and -4.25, Overvalued between -1.29 and 0.19, and Strongly Overvalued above 0.19. The current Forward P/FCF of -8.89 falls within the Strongly Undervalued range.

Zenas Biopharma Inc (ZBIO) has a current Price-to-Book (P/B) ratio of 5.36. Compared to its 3-year average P/B ratio of 1.72 , the current P/B ratio is approximately 211.66% higher. Relative to its 5-year average P/B ratio of 1.72, the current P/B ratio is about 211.66% higher. Zenas Biopharma Inc (ZBIO) has a Forward Free Cash Flow (FCF) yield of approximately -9.09%. Compared to its 3-year average FCF yield of -24.01%, the current FCF yield is approximately -62.15% lower. Relative to its 5-year average FCF yield of -24.01% , the current FCF yield is about -62.15% lower.

5.36

P/B

Median3y

1.72

Median5y

1.72

-9.09

FCF Yield

Median3y

-24.01

Median5y

-24.01

Competitors Valuation Multiple

The average P/S ratio for ZBIO's competitors is 14.03, providing a benchmark for relative valuation. Zenas Biopharma Inc Corp (ZBIO) exhibits a P/S ratio of 30.53, which is 117.62% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Nurix Therapeutics Inc

Rapport Therapeutics Inc

26.17

1.21B

SANA.O

Sana Biotechnology Inc

4.08

1.01B

TSHA.O

Taysha Gene Therapies Inc

4.03

-100.00%

1.10B

Performance Decomposition

Market capitalization of ZBIO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of ZBIO in the past 1 year is driven by Unknown.